Increasing awareness, improved healthcare access, and next-gen diagnostic tools fuel steady 5.10% CAGR growth in the HIV diagnostics market through 2032.Austin, May 10, 2025 (GLOBE NEWSWIRE) -- HIV ...

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), Gilead Sciences ...

Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall ...